Chronic Kidney Disease
Comprehensive Note for Graduate Pharmacy Students
Source: Review Article from Revista da Associação Médica Brasileira (2020)
Authors: Adriano Luiz Ammirati
Summary
Chronic kidney disease (CKD) is a highly prevalent condition (10-13% of the population) characterized by irreversible and progressive loss of renal function, associated with increased cardiovascular risk. Patients often remain asymptomatic until advanced stages, presenting complications typical of renal dysfunction. Management includes conservative treatment (for patients with GFR >15 ml/min) and renal replacement therapy (hemodialysis, peritoneal dialysis, transplantation). Conservative management aims to slow disease progression, treat complications (anemia, bone disorders, CVD), provide hepatitis B vaccination, and prepare for renal replacement therapy.
Key Pharmacist Takeaways: CKD management requires a multidisciplinary approach. Pharmacists play crucial roles in medication optimization, monitoring for nephrotoxicity, managing complications (anemia, mineral disorders), patient education, and vaccination coordination.
Definition & Diagnosis
CKD is defined as a clinical syndrome secondary to definitive changes in kidney structure/function, characterized by irreversibility and slow progression. Diagnosis requires persistence for ≥3 months of either:
- Glomerular filtration rate (GFR) < 60 mL/min/1.73 m², OR
- GFR ≥ 60 mL/min/1.73 m² with evidence of kidney damage (albuminuria, imaging abnormalities, hematuria, biopsy changes, etc.)
Albuminuria definition: >30 mg albumin in 24-hour urine or >30 mg/g albumin in spot urine adjusted by creatinine.
Major Etiologies: Diabetes, hypertension, glomerulonephritis, chronic pyelonephritis, prolonged NSAID use, autoimmune diseases, polycystic kidney disease, congenital malformations, and post-acute kidney injury.
Also Read Pathophysiology and Classification of Kidney Diseases
Classification & Staging
CKD is classified based on GFR and albuminuria categories, which together predict progression risk and guide management intensity.
Table 1: CKD Stages by GFR
| Stage | GFR (mL/min/1.73m²) | Classification |
|---|---|---|
| I | >90 | Normal or High |
| II | 60–89 | Slightly decreased |
| III A | 45–59 | Mild to moderately decreased |
| III B | 30–44 | Moderately to severely decreased |
| IV | 15–29 | Severely decreased |
| V | 3 months is classified as CKD Stage IIIB A2.
Risk StratificationThe combination of GFR and albuminuria categories determines the risk of CKD progression (Table 3 in original). Higher albuminuria and lower GFR correspond to very high risk. Risk prediction should also incorporate cause of kidney disease, age, sex, race, comorbidities, and lifestyle factors. Also Read HPLC Method Development in Pharmaceuticals EpidemiologyCKD prevalence in US adults is ~13.1%. Brazilian estimates vary, with 3-6 million potentially affected. The 2017 Brazilian Society of Nephrology census reported 126,583 patients on dialysis (prevalence ~610 per million population). Mortality: Reduced GFR accounted for 4% of global deaths in 2013 (2.2 million), with >50% cardiovascular-related. Annual dialysis mortality in Brazil is 19.9%. Screening & ReferralScreening Indications:
Assessment Includes:
Nephrology Referral Criteria:
Also Read Pharmaceutical Aseptic Area Conservative Management FrameworkFour Pillars of Conservative Management:
Multidisciplinary Team: Essential for optimal care—includes pharmacy, nutrition, nursing, psychology, and social work. 1. Slowing ProgressionStrategies:
|
